This article is more than 5 years old. Information may no longer be current.
Top 5 online stories posted in August
Click Here to Manage Email Alerts
Endocrine Today compiled a list of the top five news stories posted over the past month.
Healio.com/Endocrinology readers were interested in an updated position statement on hypertension, diacerin for reducing HbA1c, and much more.
ADA updates position statement on hypertension in diabetes
For most patients with diabetes and hypertension, a combination of in-clinic and home-based blood pressure monitoring, a BP target of less than 140/90 mm Hg, individualized antihypertensive treatment and lifestyle modification are key to reduce the risk for atherosclerotic cardiovascular disease, heart failure and microvascular complications, according to a new position statement released by the American Diabetes Association. Read more.
Diacerein safe, effective for lowering HbA1c
The immune modulator anti-inflammatory drug diacerein was safe and effective for reducing HbA1c and insulin dose in adults with type 2 diabetes, according to findings published in Diabetes Care. Read more.
SGLT2 inhibitors lower CV mortality, morbidity in diabetes
The use of SGLT2 inhibitors compared with other glucose-lowering drugs was associated with reduced risk for cardiovascular disease morbidity and mortality in adults with type 2 diabetes, study data show. Read more.
Weight loss tied to all-cause mortality
Weight loss of 15% or more and weight gain of 20% or more are both associated with increased all-cause mortality in adults, but the risk is more pronounced with weight loss, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.
FDA approves expanded CV indication for Victoza
The FDA today approved an expanded indication for the GLP-1 receptor agonist liraglutide to include language in the prescribing information that the drug can reduce risk for major adverse cardiovascular events, myocardial infarction, stroke and cardiovascular disease in adults with type 2 diabetes and established CVD, according to a press release from Novo Nordisk. Read more.